Results 31 to 40 of about 22,889 (244)

OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER [PDF]

Journal of IMAB, 2010
Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent ...
Deyan Davidov
doaj   +1 more source

Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis

Frontiers in Oncology, 2023
ObjectiveIt remains unclear what the best second-line treatment is for patients with small-cell lung cancer sensitive to previous platinum-based chemotherapy.MethodsWe systematically screened randomized controlled trials from several online databases ...
Hekai Shi, Nuojin Guo, Zeming Zhao, Ligang Liu, Tianyi Ni, Jinye Zhang, Yingjie Lu   +6 more
doaj   +1 more source

Delayed vaccine-induced CD8+ T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradication

Journal for ImmunoTherapy of Cancer, 2023
Background The survival of patients with cervical cancer who are treated with cisplatin in conjunction with the topoisomerase I inhibitor topotecan is enhanced when compared with patients treated with only one of these chemotherapeutics.
Sjoerd H van der Burg, Suzanne van Duikeren, Ramon Arens, Cornelis J M Melief, Tetje C van der Sluis, Ward Vleeshouwers, Floortje J van Haften, Iris N Pardieck, J Fréderique de Graaf, Koen van der Maaden   +9 more
doaj   +1 more source

Generation of the Camptothecin Scaffold by a Flavin‐Catalyzed Photooxidative Skeletal Reorganization

Angewandte Chemie, EarlyView.
The biosynthetic pathway of the anticancer drug precursor camptothecin involves an enigmatic skeletal reorganization from a 6/5/6 tetrahydro‐β‐carboline to a 6/6/5 pyrroloquinoline ring system. Here, we show that this transformation can be achieved by photooxidation with flavin cofactors, such as flavin mononucleotide (FMN) as catalysts.
Shenyu Liu, Zeliang Zhang, Benedikt Seligmann, Van Hung Bui, Tuan‐Anh Minh Nguyen, Thu‐Thuy T. Dang, Jakob Franke   +6 more
wiley   +2 more sources

The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment.

PLoS ONE, 2012
BackgroundTopotecan produces DNA damage that induces autophagy in cancer cells. In this study, sensitising topotecan to colon cancer cells with different P53 status via modulation of autophagy was examined.Methodology/principal findingsThe DNA damage ...
Dan-Dan Li, Ting Sun, Xiao-Qi Wu, Shu-Peng Chen, Rong Deng, Shan Jiang, Gong-Kan Feng, Jing-Xuan Pan, Xiao-Shi Zhang, Yi-Xin Zeng, Xiao-Feng Zhu   +10 more
doaj   +1 more source

Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex. [PDF]

PLoS ONE, 2010
BACKGROUND: Human topoisomerase I catalyzes the relaxation of DNA supercoils in fundamental cell processes like transcription, replication and chromosomal segregation. It is the only target of the camptothecin family of anticancer drugs.
Giordano Mancini, Ilda D'Annessa, Andrea Coletta, Nico Sanna, Giovanni Chillemi, Alessandro Desideri   +5 more
doaj   +1 more source

Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs

Canadian Respiratory Journal, 2016
Purpose. Topotecan and belotecan are camptothecin derivatives that are used to treat small cell lung cancer (SCLC). This study compared the toxicities and efficacies of belotecan and topotecan monotherapies in patients with SCLC. Methods.
Yeon Hee Park, Chae Uk Chung, Bo Mi Park, Myoung Rin Park, Dong Il Park, Jae Young Moon, Hee Sun Park, Jin Hwan Kim, Sung Soo Jung, Ju Ock Kim, Sun Young Kim, Jeong Eun Lee   +11 more
doaj   +1 more source

Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model

Drug Delivery, 2018
Intravenous (IV) topotecan is approved for the treatment of various malignancies including lung cancer but its clinical use is greatly undermined by severe hematopoietic toxicity. We hypothesized that inhalation delivery of topotecan would increase local
Philip J. Kuehl, Marcie J. Grimes, Devon Dubose, Michael Burke, David A. Revelli, Andrew P. Gigliotti, Steven A. Belinsky, Mathewos Tessema   +7 more
doaj   +1 more source

RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

Journal of Clinical Oncology
PURPOSE The phase III RESILIENT trial compared second-line liposomal irinotecan with topotecan in patients with small cell lung cancer (SCLC). PATIENTS AND METHODS Patients with SCLC and progression on or after first-line platinum-based chemotherapy were
D. Spigel, Afshin Dowlati, Yuanbin Chen, A. Navarro, J. Yang, Goran Stojanovic, Maria Jove, Patricia Rich, Z. Andrić, Yilong Wu, C. Rudin, Huanyu Chen, Li Zhang, Stanley Yeung, F. Benzaghou, L. Paz-Ares, P. Bunn   +16 more
semanticscholar   +1 more source

The Role of Cryotherapy in Vitreous Concentrations of Topotecan Delivered by Episcleral Hydrogel Implant

Pharmaceutics, 2022
Transscleral diffusion delivery of chemotherapy is a promising way to reach the vitreal seeds of retinoblastoma, the most common intraocular malignancy in childhood.
Martina Kodetova, Radka Hobzova, Jakub Sirc, Jiri Uhlik, Katerina Dunovska, Karel Svojgr, Ana-Irina Cocarta, Andrea Felsoova, Ondrej Slanar, Martin Sima, Igor Kozak, Pavel Pochop   +11 more
doaj   +1 more source